CRISPR Therapeutics AG financial data

Symbol
CRSP on Nasdaq
Location
Baarerstrasse 14, Zug, Switzerland
State of incorporation
Switzerland
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.79K % +24.3%
Debt-to-equity 17.5 % -15.2%
Return On Equity -12.2 % +37.5%
Return On Assets -10.3 % +35.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 85.4M shares +7.45%
Common Stock, Shares, Outstanding 85.3M shares +7.44%
Entity Public Float 4.1B USD -4.65%
Common Stock, Value, Issued 2.68M USD +8.4%
Weighted Average Number of Shares Outstanding, Basic 85.2M shares +7.33%
Weighted Average Number of Shares Outstanding, Diluted 85.2M shares +7.33%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 602K USD
Research and Development Expense 334M USD -15.7%
General and Administrative Expense 71.3M USD -11.8%
Operating Income (Loss) -332M USD +21.5%
Nonoperating Income (Expense) 95.9M USD +51.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -236M USD +34.4%
Income Tax Expense (Benefit) 3.12M USD +113%
Net Income (Loss) Attributable to Parent -240M USD +32.2%
Earnings Per Share, Basic -2.81 USD/shares +37%
Earnings Per Share, Diluted -2.81 USD/shares +37%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 226M USD -57.2%
Marketable Securities, Current 1.71B USD +41.1%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD
Assets, Current 1.94B USD +10.4%
Property, Plant and Equipment, Net 139M USD -11.3%
Operating Lease, Right-of-Use Asset 146M USD -6.36%
Other Assets, Noncurrent 15.9M USD +676%
Assets 2.26B USD +8.11%
Accounts Payable, Current 15.6M USD -40.4%
Employee-related Liabilities, Current 15.1M USD -5.03%
Accrued Liabilities, Current 47.2M USD -28.9%
Contract with Customer, Liability, Current 4.48M USD +28.1%
Liabilities, Current 89.8M USD -19.3%
Contract with Customer, Liability, Noncurrent 12.3M USD -22.1%
Operating Lease, Liability, Noncurrent 211M USD -7.03%
Other Liabilities, Noncurrent 3.68M USD -31.8%
Liabilities 316M USD -11.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 10.6M USD
Retained Earnings (Accumulated Deficit) -1.33B USD -22%
Stockholders' Equity Attributable to Parent 1.94B USD +12.3%
Liabilities and Equity 2.26B USD +8.11%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 110M USD +1147%
Net Cash Provided by (Used in) Financing Activities 306M USD +5561%
Net Cash Provided by (Used in) Investing Activities -97.8M USD -183%
Common Stock, Shares Authorized 132M shares
Common Stock, Shares, Issued 85.5M shares +7.41%
Common Stock, Par or Stated Value Per Share 0.03 CHF/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 318M USD +141%
Deferred Tax Assets, Valuation Allowance 228M USD +14.8%
Deferred Tax Assets, Gross 308M USD +9.43%
Operating Lease, Liability 239M USD -2.21%
Depreciation 19.3M USD -6.76%
Payments to Acquire Property, Plant, and Equipment 721K USD -76.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -222M USD +34.3%
Lessee, Operating Lease, Liability, to be Paid 323M USD -5.17%
Property, Plant and Equipment, Gross 206M USD +0.81%
Operating Lease, Liability, Current 16.9M USD +12.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 28.8M USD +8.67%
Lessee, Operating Lease, Liability, to be Paid, Year One 28.7M USD -1.94%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 84M USD -12.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 29.4M USD +12%
Deferred Tax Assets, Operating Loss Carryforwards 133M USD +12.6%
Unrecognized Tax Benefits 44.1M USD +27.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 28.7M USD +7.19%
Depreciation, Depletion and Amortization 4.83M USD -4.32%
Deferred Tax Assets, Net of Valuation Allowance 80.2M USD -3.38%
Share-based Payment Arrangement, Expense 83M USD -2.78%